Table 1.

Distribution of Participant Responses by MPATH-Dx Class and Treatment Consideration^a

	Suggested Treatment Consideration Made by Participant for the Case
	I: No further treatment	II: Re-excise <5mm margins	III: Re-excise ≥5mm to <1cm margins	IV/V: Re-excise ≥1cm marginsb	Total
MPATH-Dx Classification based on Participants’ Write-in Diagnosis
Presuming Least Severe Diagnosis (when needed)c
Class I: No apparent risk for continued local proliferation and adverse outcome	89 (67.9)	40 (30.5)	2 (1.5)	0 (0.0)	131
Class II: Low level risk for local proliferation of remaining cells	2 (3.8)	41 (78.8)	9 (17.3)	0 (0.0)	52
Class III: Higher likelihood of local tumor progression and greater need for intervention	0 (0.0)	30 (21.1)	96 (67.6)	16 (11.3)	142
Class IV/V: Invasive melanoma stage T1a or ≥T1b	0 (0.0)	3 (1.0)	29 (9.4)	277 (89.6)	309
Total	91	114	136	293	634
Presuming Most Severe Diagnosis (when needed)c
Class I: No apparent risk for continued local proliferation and adverse outcome	86 (87.8)	12 (12.2)	0 (0.0)	0 (0.0)	98
Class II: Low level risk for local proliferation of remaining cells	3 (6.4)	43 (91.5)	1 (2.1)	0 (0.0)	47
Class III: Higher likelihood of local tumor progression and greater need for intervention	2 (1.3)	55 (34.8)	96 (60.8)	5 (3.2)	158
Class IV/V: Invasive melanoma stage T1a or ≥T1b	0 (0.0)	4 (1.2)	39 (11.8)	288 (87.0)	331
Total	91	114	136	293	634

^aValues expressed as count (row percent)

^bIncludes sentinel lymph node sampling and/or adjuvant therapy (e.g. interferon) as additional treatment responses

^cWrite-in responses that included differential diagnoses were classified using two scenarios, one presuming the least severe diagnosis and the other presuming the most severe diagnosis